Quantitative analysis confirmed that the combination of FAK and MEK inhibitors resulted in a statistically significant reduction in tumor size relative to the monotherapy arms, underscoring the potential of this combination therapy in effectively targeting glioblastoma (Figure 8C). This evidence concerns the gene MAP2K7 and neoplasm.